Tizon, Candido T.

HRN: 14-84-09  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/12/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/12/2024
03/18/2024
IV
4.5g LD, Then 2.25g
Q8h
CAP MR, Covid 19 Infection, T/C UTI, (Ceftriaxone Given Last Admission Feb 2024)
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: